MKI67 and central nervous system cancer: Recipient efficacy for predicting advanced and secondary glioma from rD, rf, rD∗, rCBF, and Ki-67 LI raises AUCs of 0.819, 0.747, 0.719, 0.836, and 0.907, respectively.